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1. Introduction
This chapter will give an overview of the magnetic resonance imaging (MRI) modalities used
in locally advanced rectal cancer (LARC) staging with an emphasis on the role of MRI and its
significance for planning an effective therapeutic strategy for the individual patient.
Specifically, the aim of this chapter is to present a brief review about:
1. Methodologies of Magnetic Resonance Imaging in LARC staging
a. Morphologic MRI
b. Functional MRI
i. Dynamic Contrast Enhanced MRI (DCE-MRI)
ii. Diffusion Weighted MRI (DW-MRI)
2. The role of MRI in diagnosis, staging, evaluation of response of neoadjuvant treatment,
follow-up post surgery.
This chapter will be organised in the following sections. First, in order to better define the role
of MRI in LARC management, we will briefly describe the epidemiological scenario and
therapeutic options, with an emphasis on issues in which MRI is relevant. Second, we will
describe morphologic and functional MRI including DCE-MRI and DW-MRI. Finally, a
systematic review of the literature concerning MRI, CT and PET for LARC management will
be presented.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Epidemiology
Colorectal cancer is the third most common cancer worldwide [1], which includes cancers of
the colon, rectum, rectosigmoid junction and anus. Specifically, in men it represents the third
commonest neoplasm after prostate and lung cancers while in women it is the second major
cause of morbidity and mortality, following breast cancer.
In recent years, mortality rates have decreased due to several factors, including less exposure
risk factors, more possibility of prevention and “early diagnosis” followed by an effective
management of the disease. In particular, major changes in therapeutic management are given
by the standardization of operative procedures and the introduction of adjuvant and neoad‐
juvant therapy [2-7], able to reduce recurrence risk and tumor size.
Cancers are characterized by profound spatial and temporal heterogeneity in their biologic
characteristics. Most invasive cancers typically have alterations in cell physiology that promote
malignant growth [2-7]. Rectal cancer is the result of a complex interaction between genetic
and environmental factors and it is defined as a tumor whose aboral margin measured with
the rigid rectoscope is 16 cm or less from the anocutaneous line. This distance serves to classify
rectal cancer into tumours of the upper third (12–16 cm), the middle third (6–12 cm), and the
lower third (<6 cm) [26] according to the Union for International Cancer Control (UICC).
The mesorectal fascia is an important anatomic landmark for the diagnostic evaluation of local
tumor extent [26]. It is a connective tissue sheath that surrounds the rectum and the perirectal
fatty tissue and acts as a natural barrier for tumor spread.
A locally advanced tumor often describes a tumor extending beyond the rectal wall with
infiltration to surrounding organs or structures, and/or perforation of the visceral peritoneum.
It includes bulky T3 tumors with threatened circumferential margins or T4 tumors, tumors
with growth onto the peritoneal surface. A radiological T4 tumor is considered when detected
growing outside the mesorectal fascia, while a T3 tumor refers to a tumor invading through
muscularis propria [26].
These tumors have traditionally been looked upon as “unresectable”, although previous
staging, due to the wide tumor extension. However, when it is possible, these tumors cannot
be resected without leaving microscopic or gross residual disease at the local site because of
tumor adherence or fixation to that site.
3. Therapeutic options
In LARC accurate and detailed anatomic information in tumor extent is essential not only for
the selection of the patients for neoadjuvant chemotherapy and radiation therapy to achieve
tumor shrinkage but also for the optimal surgical procedure planning. Moreover, the treatment
for patients with locally advanced and recurrent rectal cancer differs significantly from patients
with rectal cancer restricted to the mesorectum.
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Adequate preoperative imaging of the pelvis is therefore important to identify those patients
who are candidates for multimodality treatment, including preoperative chemoradiation
protocols, intraoperative radiotherapy, and extended surgical resections. Much effort should
be made to select patients with these advanced tumors for treatment in specialized referral
centers. This has been shown to reduce morbidity and mortality and improve long-term
survival rates.
Two main therapeutic options can be considered according to different pathological stages
presented [13-35]:
1. Total mesorectal excision (TME): using this surgical technique, the rectum is resected
together with all surrounding lymphatic pathways, lymph nodes, mesorectal fatty tissue,
and the mesorectal fascia while the parietal pelvis fascia and the pelvic splanchnic nerves
are spared. This surgical technique minimizes the chance of tumor being left inside;
2. Adjuvant/neoadjuvant therapy: the aims of adjuvant or neoadjuvant therapy are to enable
or facilitate total tumor resection even in advanced disease, to prevent local tumor
recurrence, and to minimize the risk of distant metastases.
The majority of patients with primary rectal cancer have a tumor located within the mesorectal
fascia, which is generally treated with total mesorectal excision (TME). Results of TME surgery
are excellent with a significant reduction in local recurrences when preoperative short-term
radiotherapy (5 x 5 Gy) is delivered one week prior to surgery [27]. In ≈10% of all rectal cancer
patients the tumor extends into or beyond the enveloping fascia of the mesorectal compart‐
ment.
Often these tumors infiltrate adjacent structures and therefore have a higher risk to develop a
local recurrence [28].
Patients with these primary locally advanced or recurrent rectal cancer are difficult to treat
with surgery alone, but outcome has significantly improved using multimodality treatment.
Although preoperative and adjuvant therapy is important in these patients, the mainstay of
treatment in rectal cancer is complete surgical removal of the tumor. In both locally advanced
and recurrent rectal cancers, this involves not only the removal of the total mesorectum, but
en bloc resection of involved structures is often needed.
Although postoperative chemoradiotherapy (CRT) has long been recommended for locally
advanced and node positive rectal cancer patients, preoperative treatment is now widely used
worldwide. In many European centers, radiotherapy only was used as neoadjuvant treatment
for locally advanced rectal cancer, but the addition of chemotherapy has recently demonstrated
to improve local control in two large randomized trials [30,31]. Addition of 5-FU and leuco‐
vorin to preoperative radiation slightly increased the amount of acute toxicity in T3 to T4
resectable rectal cancer patients [32]. However, it increased the number of complete responses
and decreased the local recurrence rate after 5 years.
Not only new chemotherapeutic drugs, but also a vascular endothelial cell growth factor-
(VEGF-) specific monoclonal antibody in combination with chemoradiation was recently
reported by Willet et al [32] to lead to considerable downstaging of the tumor. Other modalities
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such as the use of intensity-modulated radiotherapy (IMRT), which has the potential of more
accurate delivery of higher radiotherapy dosages, thus avoiding the damage of critical
structures surrounding the tumor, are being tested in rectal cancer.
Total pelvic exenteration (TPE) is a widely used technique for resection of locally advanced or
recurrent rectal tumors invading the bladder and/or prostate. Longterm survival with excellent
local control is possible after TPE for primary locally advanced rectal cancer [33-35]. The
majority of resections in primary cancer are without microscopic or macroscopic residual
tumor mass, which clearly justifies the use of TPE in selected patients with primary disease.
Although current guidelines for colorectal cancer surgery advocate TPE, only one third of the
patients in a recent study based on SEER (survival, epidemiology and end results) data
underwent the appropriate surgical resection.
These patients had a clinically significant overall survival benefit with no increase in short-
term mortality compared with similar patients who did not receive a multi-visceral resection.
Local control in rectal cancer patients is related to the dose of irradiation, but because of toxicity
to radiosensitive organs (such as small bowels), the external radiation dose should not exceed
60 Gy. A combination of external radiation and intraoperative radiation therapy (IORT) allows
the safe delivery of higher effective doses of irradiation than can be delivered with external-
beam only techniques. IORT is used when resection margins are narrow or involved with
tumor cells and can be applied very specifically to an area at risk, under direct visual control,
and with the ability to shield the surrounding structures from radiation. The biological
effectiveness of single-dose IORT is considered to be as effective as 2 to 3 times the equivalent
dose of fractionated radiotherapy.
3. Role of MRI vs other modalities
3.1. Generalities
Imaging techniques play a pivotal role in the strategies for management of locally advanced
rectal cancer patients. The role of diagnostic imaging is to perform a loco-regional staging as
accurate as possible in both evaluation of infiltration and extension degrees of disease. Image
features also enable preoperative assessment of important prognostic outlines, which may
guide patient selection for neoadjuvant therapies. Moreover, imaging plays an important role
in therapeutic assessment, surveillance after surgery, and evaluation of suspected disease fall-
out. To date, imaging innovations have led to improvements in spatial and contrast resolution,
increased data acquisition speeds, and enabled complex image to achieve excellence in
anatomic resolution.
There are many different imaging modalities suitable for rectal cancer staging, tumour location
and restaging but not all of them have the same accuracy for each indication. An optimal
visualization of tumor volume and of its surrounding anatomical structures is necessary for
any local cancer treatment. This issue is particularly important for radiotherapy treatment
planning in order that a geographical miss can be avoided and the tumor adequately treated.
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Among the imaging methods available Magnetic Resonance Imaging (MRI) is currently the
modality of choice because of its capacity to perform local staging, since it enables evaluation
of anatomic aspects and prognostic factors that are key to choosing the appropriate surgical
approach and determining the need for neoadjuvant treatment.
3.2. MRI physical basics
MRI is an imaging technique based on the different magnetic properties of tissues in the body.
The exposure to a high intensity magnetic field determines the alignment of the hydrogen
nuclei (protons) along the magnetic field axis itself. The emission of radio frequency pulses
causes a shift from this alignment, which tends to reconstitute as soon as the impulse is
interrupted. This phenomenon leads to a variation in energy level of the charges, which can
be translated into a signal whose decoding is the basis of the generation of magnetic resonance
images. All this is based on specific parameters that describe these steps of energy levels
(including the so-called "relaxation times T1 and T2"), as well as on the concentration of protons
within a given tissue.
Pulses sequences are used to obtain the different MR images, sequences consisting of radio
frequency pulses with different characteristics in terms of duration, frequency and type of
sampling of the resulting signal.
In the various biological tissues, the characteristics of the magnetic resonance signal are
influenced mainly by the content of hydrogen atoms (whose nuclei are composed of only one
proton). Since water is the most abundant molecule in the body and contains hydrogen atoms,
it can be reasonably stated that the increase or the decrease of water in a given tissue is almost
always at the basis of changes in signal intensity when using sequences of magnetic resonance
imaging.
Where tissue contrast depends primarily on electron density, the tissue contrast obtained by
MRI can be extensively varied by imaging the intrinsic tissue properties, as spin-lattice and
spin-spin relaxation times, protons density, magnetization transfer, separately or in combina‐
tion, using a number of pulse sequences, which in turn can be altered by an essentially infinite
number of different experimental conditions. These MR parameters can be exploited and
tailored to facilitate optimal tumor visualization and evaluation. Another feature of MRI is
that cortical bone does not give rise to an MR signal and therefore appears hypointense. This
is because cortical bone contains calcium and there are few hydrogen protons to provide an
MR signal. Furthermore, MRI can obtain detailed anatomical images in any desired plane, also
acquiring 3D or volumetric image sets. Therefore, the superior soft tissue definition provided
by MRI, together with its unrestricted multiplanar, volumetric, vascular and functional
information has benefits for 3D treatment planning.
3.3. Comparison of MRI and CT
Computed Tomography (CT) scanning is an imaging technique able to reproduce a 3D image
of internal organs by irradiating X-ray. In LARC treatment CT shows the effective tumor size
and its possible dissemination to internal organs. Although CT imaging provides excellent
Role of Magnetic Resonance Imaging in Locally Advanced Rectal Cancer
http://dx.doi.org/10.5772/56831
57
definition between structures with different electron density or X-ray attenuation character‐
istics, it distinguishes poorly between structures with similar electron density such as different
soft tissue structures, including tumors, unless there is an obvious fat or air interface [60]. The
major advantage of MRI compared with CT is in its superior ability to demonstrate and
characterize soft tissues that have similar electron densities. In this manner, MRI may provide
better delineation not only of the tumor extent, but also of the adjacent critical soft tissue organs.
This will allow conformal planning to enhance its therapeutic ratio by more accurately
targeting the tumor, avoiding the organs at risk and subsequently improving local control.
3.4. Comparison of MRI and PET/CT
In LARC patient management detection of tumor sites throughout the body is needed with
high sensitivity and specificity in order to have accurate information about the local extent. As
discussed in the previous section, an accurate tumour visualization can be performing using
MRI techniques. An additional value should be given to consider the combination of Positron
Emission Tomography (PET) and CT [61]. PET/CT is a diagnostic procedure that allows to
obtain morphological images of the human body provided by CT and images of the tissue
metabolic processes provided by PET by means of a co-registration system.
Tissues appear differently on PET and on CT images. CT displays anatomy with high spatial
resolution, but with low contrast resolution for soft tissues, while PET visualizes pathological
sites with high contrast resolution but a limited spatial resolution and surrounding normal
anatomical structures are hardly visualized. The combination of metabolic activity with anatomic
localization achievable with PET/CT improve accuracy over that of PET or CT alone [62].
4. Role of MRI in LARC
In the recent years MRI has undergone significant transformations resulting from technolog‐
ical innovation that have taken place as the introduction of high-field magnets, powerful
gradients, multi-channel phased array coils and endorectal coils improvement. These techno‐
logical developments have certainly allowed the executing of high quality diagnostic studies
due to the high spatial resolution and contrast obtained, to the possibility of identification and
distinction of rectal wall layers, and to the possibility of assessing perirectal and sphinteric
structures. Mainly, superficial endorectal coils are currently able to identify various layers of
lower rectum wall. MRI is thus the ideal technique for rectal cancer staging, combining the
capabilities of an accurate loco-regional staging to the outlook and multi-planar properties.
In conclusion, MRI can currently stage with high accuracy the T parameter (related to the
degree of tumor infiltration) due to the possibility offered by the endorectal coil to recognize
the wall layers, resulting also extremely useful in planning surgery and in prognostic stratifi‐
cation, owing to the ability to accurately identify mesorectum and the distance between
mesorectal fascia and neoplasia. Furthermore the high temporal resolution of last generation
devices allows to perform perfusion and dynamic studies after gadolinium administration that
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allow to detection of the residual tumor after neoadjuvant therapy and to diagnose recurrences,
distinguishing them from fibrosis.
4.1. Morphological MRI
As regards the topographic relationship of the tumor with the mesorectal fascia can be
adequately established with morphologic MRI [26]. The advent of powerful gradient systems
and, above all, the development of high-resolution phased array surface coil systems in recent
years brought the breakthrough in the staging of rectal cancer by MRI. The use of these phased-
array surface coils combines a very high spatial resolution with a large FOV that allows not
only detailed evaluation of the intestinal wall but also depicts surrounding anatomy including
the mesorectal fascia.
A standard phased-array morphologic MRI protocol for LARC staging (including T-N stage
and CRM evaluation) consists of T2-weighted coronal, transversal and sagittal turbospin-echo
MR sequences with high spatial resolution (Fig. 1) [26].
Figure 1. (a) A heterogeneous irregular thickening along the entire rectal wall is well shown on T2w axial pre-pCRT
scan (arrowheads). (b) After pCRT, a hypo-intense spiculated area with thin digitations into peri-rectal fat is visible on
T2w axial scan (arrowheads). (c) In the same patient, multiple irregular rectal wall thickening are shown on T2w sagit‐
tal pre-pCRT scan (arrowheads). (d) A single hypo-intense area, showed also in (b) is pointed by arrowheads, suspect‐
ing for a residual post-pCRT tumor focus (arrowheads).
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An adequate, state-of-the-art MRI staging classification is capable to predict whether a tumor-
free CRM is likely to be achieved or not [26]. In this way one would be able to differentiate
patients with minimal mesorectal infiltration in whom neoadjuvant therapy is not mandatory
from patients who would definitely benefit from neoadjuvant therapy because the mesorectal
fascia is infiltrated or at risk.
The common use of total mesorectal excision (TME) and the shift from a postoperative to a
preoperative chemo-radiotherapy (pre-CRT) approach have substantially reduced the risk of
local recurrences, increasing curative resection and the rate of anal sphincter preservation and
improving local control and overall survival rates [13-18].
4.2. Functional MRI
Although morphological tumour assessment performed by MRI has been repeatedly shown
to be the most accurate modality in evaluating the presence of a positive circumferential
resection margin (CRM), MRI is considered not to be conclusive in pre-CRT tumor response
evaluation since histopathological downstage is not always associated with tumour effective
reduction [17]. The main difficulty regarding post-chemoradiation MRI includes discrimina‐
tion of active tumour and post-treatment fibrosis, particularly when differentiating stage T2
and stage T3 carcinomas, according to different recurrence and overall survival rates between
Low Risk (T1/T2N0) and Intermediate Risk (T3/N0) as reported by Gunderson et al. [23-24].
Several studies have shown the potential of functional [diffusion- or perfusion] weighted
imaging to predict the response to adjuvant or neoadjuvant therapy [5–7,19].
In fact, it has long been known that the pathophysiology and aggressiveness of a tumor are
determined not only by the macroscopic tumor extent but also by other factors such as tumor
microcirculation and angiogenesis.
4.2.1. DCE-MRI
Previous considerations support a Dynamic Contrast Enhanced-Magnetic Resonance Imaging
(DCE-MRI) approach that could gain a renewed role to MRI adding functional data to the
morphological examination. DCE-MRI has been reported by many authors as a tool potentially
able to permit an evaluation of pre-CRT effectiveness basing on the strict relationship between
tumor growth and angiogenesis [6-7,24-25].
DCE-MRI is gaining a large consensus as a technique for diagnosis, staging and assessment of
therapy response for different types of tumours, due to its capability to detect highly active
angiogenesis. It is well known that angiogenesis is a key factor in the growth and dissemination
of cancer; characterization of the angiogenic status of the tumour on an individual patient basis
could allow for a more targeted approach to treatment of rectal cancer [24].
More specifically, in the case of rectal cancer, previous trials have provided the proof of
principle that inhibition of angiogenesis has the potential to enhance the effectiveness of the
treatment for this disease. In vivo imaging techniques capable to assess tumour perfusion have
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the potential to improve the management of treatment for patients with rectal cancer
[6-7,24-25].
Angiogenesis is a key factor for the growth and dissemination of solid tumors and is a
prognostic marker in CRC. Neovascularization arises early in the adenoma–carcinoma
sequence via upregulation of vascular endothelial growth factor. Tumor angiogenesis is
characterized by structurally abnormal blood vessels that are thin, fragile, tortuous, and
hyperpermeable. They have a chaotic, heterogeneous intratumoral distribution. Abnormal
vascularity often extends beyond the tumor boundaries into surrounding tissues.
DCE-MRI techniques inform on tissue perfusion and vascular leakage (Fig. 2). T1- or relaxivity-
based MR sequences are sensitive to the presence of dilute contrast medium in the extrava‐
scular– extracellular space. In most tumors, low-molecular-weight contrast media readily
diffuse from the blood into the extravascular– extracellular space at a rate determined by
perfusion and the capillary permeability and surface area.
The most commonly used model for analyzing DCE-MRI data uses two compartments where
the contrast agent resides (blood plasma and extravascular– extracellular space). Ktrans (volume
transfer constant between the blood plasma and the extravascular–extracellular space, the
washin rate, measured in minutes−1) and kep (rate constant between the extravascular–
extracellular space back to the blood plasma, the washout rate, measured in minutes−1)
determine the transport between these two compartments.
Physiologically, Ktrans indicates a variable combination of the flow and permeability properties.
For blood vessels where leakage is rapid (that is, when the extraction fraction during the first
pass of the contrast agent is high, as typically is found in tumors), perfusion will determine
contrast agent distribution and Ktrans approximates to tissue blood flow per unit volume. There
are circumstances in which transport out of the vasculature does not significantly deplete
intravascular contrast medium concentration (that is, tissues with lower first-pass extraction
fraction). This is typically found after treatment with chemotherapy or late after radiotherapy
and in fibrotic lesions, and in these situations, Ktrans approximates to the product of permea‐
bility and the surface area (permeability surface area product).
4.2.2. Diffusion-weighted imaging DWI-MRI
At present, the use of diffusion-weighted imaging (DWI) incorporated into a standard MR
protocol is gradually increasing because of its proven benefit not only for tumor detection/
characterization  but  also  for  monitoring  treatment  response  (8–12).  Diffusion-weighted
imaging measures water diffusion characteristics, which are dependent on multiple factors
such as cell density, vascularity, viscosity of extracellular fluid, and cell membrane integri‐
ty  (12).  By  quantifying  these  properties  and  expressing  them  as  an  apparent  diffusion
coefficient (ADC), DWI could potentially be used as an imaging biomarker to better select
patients with poor prognosis who will truly benefit from a more aggressive neoadjuvant
treatment  (8-12).  In  literature  it  was  demonstrated  that  ADC  values  of  rectal  cancers
significantly correlate with prognostic factors including the MRF status, the nodal stage and
the histological differentiation grade.
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The movement of water molecules in biologic tissues is restricted because their motion is
modified and limited by interactions with cell membranes and macromolecules. Water-
molecule motion in tissues can be assessed by applying diffusion- weighting gradients to T2-
weighted sequences. This process entails the application of two balanced gradients placed
symmetrically about a focusing 180° pulse. Water molecules that have not moved during the
time taken to apply the first gradient will have acquired phase shifts that are exactly cancelled
out by the proceeding second gradient; thus, there is no net additional signal loss induced by
the application of the paired diffusion gradients. For water molecules that have moved during
the application of the first gradient, however, the acquired phase shifts will not be cancelled
out by the second gradient; residual phase incoherence will result in net losses of signal. Hence,
the motion of water molecules is detected as attenuation of the measured signal intensity on
DWI (Fig. 3).
The sensitivity of the DWI sequence to water motion can be varied by changing the parameter
known as the b value (measured in s/mm2), which is proportional to the gradient amplitude,
duration of the applied gradient, and time interval between the paired gradients. DWI can be
Figure 2. T1w post-contrast scan obtained on the same patient in fig. 8, before (a)-(b) and after (c)-(d) pre-CRT. The
analysis of TIC calculated on a ROI, drawn outside the rectal wall where on T2w scans (fig. 8) tumor clearly spreads into
peri-rectal fat pad, confirm this suspect showing a rapid CA intake and a fast discharge (b). After pre-CRT, on the same
areas showed on T2w scans (fig. 8) no pathological CA uptake is present confirming that hypo-intense tissue visible on
T2w scans are tumor nests but only residual inflammation due to pre-CRT. This patient was considered as a Responder.
Histopathology showed a TRG 1.
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exploited in clinical practice to provide indirect assessments of tissue properties such as
cellularity, gland formation, perfusion, and cell death. In general, the greater the cell density
per high power field, the more impeded will be tissue water diffusion. Diffusion-weighted
signal is derived from the motion of water molecules within the extravascular–extracellular
space and intravascular space with some component from intracellular space water. The
relative contribution of each space to the derived signal varies from tissue to tissue. In highly
vascular tumors, intravascular water diffusion will account for a significant proportion of the
diffusion-weighted signal. In highly glandular tissues, such as the pancreas and salivary
glands, significant signal contributions arise from glandular water.
By performing DWI using different b values, quantitative analysis is possible with the
calculation of the apparent diffusion coefficient (ADC, measured in μm/s). Areas of restricted
diffusion show low ADC values. ADC values are inversely correlated with tumor cellularity
and reductions in ADC correlate with response to cytotoxic therapy.
Areas retaining high signal intensity on high-b-value images usually (but not always) indicate
highly  cellular  tissues  such  as  tumors.  Normal  tissues  including  lymph  nodes,  spleen,
nervous  tissues,  adrenal  glands,  bowel  mucosa,  and  endometrium may show the  same
findings. Lower-signal-intensity regions are seen in most organized normal tissues, cystic
spaces, and vessels. However, high signal intensities on high-b-value images are not always
reliable  indicators  of  increased  cellularity  on  their  own.  Occasionally,  fluid,  edema,  or
mucinous materials remain of high signal intensity because of high proton density. This
observation  is  called  T2-shine  through,  but  this  effect  can  be  detected  easily  by  noting
corresponding high signal on ADC maps.
There is growing interest in the application of DWI for the evaluation of CRC. DWI aids in
detection of lesions, particularly when lesions are small. High-b-value DWI may be a useful
tool for detecting and defining tumor extent.
DWI has been shown to be feasible as an early marker of treatment response because cell death
and vascular alterations typically occur before size changes. Increases in ADC values with
Figure 3. (a) Axial diffusion weigthed imaging b=0, (b) Axial diffusion weigthed imaging b=800. Hyperintensity diffu‐
sion weigthed imaging is consistent with the diagnosis of tumor.
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treatment reflect decreases in cellularity and thus provide indirect assessment of chemothera‐
py induced cell death. It has been reported that transient decreases in ADC may occur early in
treatment related to cellular swelling, reduction in blood flow, or reduction in the extravascu‐
lar– extracellular space due to dehydration. However, early decreases in ADC values are not
consistently seen, and it has recently been reported that increases in ADC value with therapy
response occur within 3–7 days in responding CRC patients treated with chemotherapy.
Responders had a lower ADC at presentation than non responders. Higher pretreatment ADC
values in nonresponders may reflect necrotic tumors that are more resistant to therapy because
of concomitant hypoxia. Similarly, for CRC liver metastases, a higher pretreatment ADC is
also predictive of poor response.
5. A systematic review
5.1. Methodologies
A systematic literature search was performed to identify English-language studies and articles
concerning different diagnostic imaging methodologies available in locally advanced rectal
cancer disease after radiation therapy. Data were identified using PubMed database with the
following keywords: “locally advanced rectal cancer, magnetic resonance imaging, CT
planning, PET imaging”. This yielded 309 titles. Articles, reviews and studies that did not
present data about specificity and sensibility of tests treated were excluded. Due to the small
number of studies for each imaging modality, there was not set a minimum number of patients
as an inclusion criteria. For this reason, a total number of 12 titles were considered as studies
included in the research.
Details regarding the number of patients, imaging modality investigated, the accuracy values
and parameters examined of the studies were recorded. Cascini et al. [41] evaluated 18F-FDG
PET to assess the effect of chemoradiation therapy in thirty-three patients with LARC proved
disease. They correlate the change in tumor 18F-FDG standardized uptake value (SUV) during
and after preoperative radiotherapy with the pathologic response achieved.
The accuracy of CT and MRI in restaging rectal cancer after preoperative chemoradiation in
order to plan optimal therapy was performed in Martellucci et al. [42] study, in which thirty-
seven consecutive patients undergoing neoadjuvant therapy were evaluated. Considering the
depth of invasion after treatment only in neoplasia with stage T3 they found CT agree with
histopathology in 19 cases and MRI in 10/12 cases.
Denecke et al. [46] compare CT, MRI and FDG-PET examining a total of twenty-three patients
with T3/4 rectal cancer. Response criteria were a change in T category and tumour volume for
CT and MRI and a change in glucose uptake for FDG-PET. Their results in sensitivity and
specificity suggest that PET is superior to CT and MRI in predicting response to preoperative
multimodal treatment of LARC.
A prospective analysis to evaluate tumor response with 18F-FDG PET in twenty-seven patients
with biopsy-proven rectal adenocarcinoma was conducted by Leibold et al. [47]. They found
Colorectal Cancer - Surgery, Diagnostics and Treatment64
of the total 27 patients, 11 (41%) had pathologic complete response; 16 (59%) had suboptimal
response. They evaluate the ability of change in 4 specific PET parameters to predict pathologic
response: the maximum SUV in the region of interest, SUVmax; the average SUV throughout
the entire region of interest, SUVavg; the summed metabolic rate of the tumor, TLG; the virtual
graded global assessment of response, VRS.
Chien-Chih Chen et al. [37] evaluated the correlation between pathological verified tumor
stage and clinical stage predicted by MRI. The overall predictive accuracy in T stage was 52%,
whereas overstaging and understaging occurred in 38% and 10% of patients, respectively.
Another study regard the MRI accuracy was conducted by Dresen et al. [45] using T2- weighted
MR images obtained before and after radiation therapy and correlating findings with histo‐
pathology results.
Kristiansen et al. [39] investigated the possibility of using PET/CT to predict the histopatho‐
logic response in 30 patients with LARC treated with a combination of radiotherapy and
concurrent Uftoral® and leucovorine. PET/CT correctly identified six of eight patients,
specificity 75%, with complete pathologic response.
To evaluate the correlation between the change of SUVmax and of apparent diffusion coefficient
(ADC) before and after neoadjuvant therapy, thirty patients with locally advanced rectal
cancer were recruited in Ippolito et al. [40] analysis, in which all the patients underwent a
whole body 18F-FDG PET/CT scan and a pelvic MR examination including DW imaging for
staging therapy.
Table 1 summarizes the main characteristics of the examined methodologies in locally
advanced rectal cancer studies.
Study Modality No.Patients Parameters
C. C. Chen et al. [37]
T. Denecke et al. [46]
G. L. Cascini et al. [41]
C. Capirci et al. [38]
C. Kristiansen et al. [39]
R. Rosenberg et al. [44]
A. Suppiah et al. [36]
R. C. Dresen et al. [45]
T. Leibold et al. [47]
D. Ippolito et al. [40]
J. Martellucci et al. [42]

















































Table 1. Summary of the main characteristics of includes studies about different methodologies used in LARC
diseases. Per each study the table reports: imaging modality used; number of patients examined; parameters
examined; sensitivity and specificity methodology values.
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5.2. Summary ROC curves and Forest Plots
In order to assess individual methodology in LARC treatment, Summary Receiver Operating
Characteristic (SROC) curves have been realized, Fig. 4. ROC curves is a statistic technique for
displaying, organizing and selecting classifiers based on their performance.
Figure 4. Estimated Summary ROC curves and original data points for four imaging techniques. MRI= magnetic reso‐
nance imaging, CT= computed tomography, PET= Positron emission tomography, PET/CT= positron emission tomog‐
raphy and computed tomography.
ROC analysis was performed through the study of the function that links the probability to
obtain a true-positive result in the disease like class, i.e. the sensitivity, to the probability to
obtain a false-positive result in the non-diseased class, linked to the specificity. In this way a
graphical 2D representation that shows the false-positive proportion in x-axis and true-positive
proportion in y-axis, relatively to values obtained from each test applied.
For each modality, a model was obtained that was adjusted for significant variables that were
set to 1, indicating the ideal design versus 0, as appropriate, Fig. 4. The position of the summary
ROC curve indicates the difference in diagnostic performance among the imaging modalities.
A summary ROC curve located near the upper left corner indicate rte better diagnostic
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modality, while a summary ROC curve for a worthless modality is represented by the bisector,
also named change line.
Another additional graphical representation realized is the Forest Plot, Fig. 5, which shows
the sensitivity and specificity estimates of the results for each study. It is composed of a plot
of the measure of effect for each of these studies incorporating confidence intervals represented
by horizontal bars. The confidence interval expresses the precision level associated with the
parameter estimation: the more is small, the more indicates that the prediction is accurate. In
this analysis confidence intervals are computed with a probability of containing the true effect
size equal to 95%. The blue square represents the point estimate, i.e. the sensitivity or specif‐
icity.
Figure 5. Forest Plot of MRI, CT, PET and PET/CT sensitivity and specificity estimates and their confidence intervals
(95%).




The objective of this statistical analysis was to evaluate the diverse methodologies (MRI, PET,
PET/CT, CT) in LARC management. In particular, in our analysis we considered the accuracy
in assessing the therapy response.
Although, the ROC curves analysis showed that PET has the best accuracy in term of sensitivity
and specificity it should be noticed that only three studies have been retrieved from the
literature.
However, in agreement with the intuitive considerations MRI and PET/ CT showed a high
diagnostic accuracy and their results are also more reliable than PET because the statistical
analysis has been carried out on a larger number of studies (6 studies for MRI with a total of
239 patients and 5 studies for PET/CT with a total of 176 patients).
The number of studies for CT is very small to draw detailed conclusions.
In conclusion we could state that a greater number of studies should be performed in the future
for each modalities to improve the reliability of any conclusion.
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